HLA
CRSP icon

Hamilton Lane Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Hamilton Lane Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,468
Closed -$400K – 84
2021
Q2 		$400K Buy
+2,468
New +$300K 0.13% 64
2020
Q4 		– Sell
-10,037
Closed -$839K – 51
2020
Q3 		$839K Buy
+10,037
New +$890K 0.41% 31
2017
Q4 		– Sell
-23,775
Closed -$425K – 57
2017
Q3 		$425K Buy
+23,775
New +$431K 0.29% 41

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Hamilton Lane Advisors's CRSP Position: Q3 2021 in Review

Hamilton Lane Advisors sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 2,468 shares — an estimated $400K sold.

Hamilton Lane Advisors first reported a position in CRSP in Q3 2017 and held it in 3 quarters. The position peaked at $839K in Q3 2020. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • Hamilton Lane Advisors reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Hamilton Lane Advisors sold 2,468 CRISPR Therapeutics shares in Q3 2021, an estimated $400K.
  • Hamilton Lane Advisors first reported a position in CRISPR Therapeutics in Q3 2017 and held it in 3 quarters.
  • Hamilton Lane Advisors's CRISPR Therapeutics position peaked at $839K in Q3 2020.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on Hamilton Lane Advisors's 13F filing for Q3 2021, filed 14 Oct 2021.